← All trials
NCT05244460
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2021
- Primary completion
- Dec 2, 2022
- Completion date
- Jan 31, 2023
- First posted
- Feb 17, 2022
- Last posted
- Feb 17, 2022
- Enrollment
- 45
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mercy Health Partners, CincinnatiLead sponsor
- Mercy Health Partners, CincinnatiOverall official - principal investigator
- Lake Erie College of Osteopathic MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.